0

Close
 
Upcoming Allied Market Research
2023
Bulbospinal Muscular Atrophy Drugs Market

Bulbospinal Muscular Atrophy Drugs Market

by Product (Leuprorelin, Dutasterid, Others) and by End User (Hospitals, Homecare, Specialty Clinics, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032

LS : Pharmaceuticals
Report Code: A11915
Nov 2023 | Pages: NA
Tables: NA
Charts: NA

  • Formats*:

  • pdf

    Single User License, Five User
    License & Enterprise User License

  • xls

    Data Pack Excel License

  • ppt

    It comes with the additional cost
    of $2500.00 contact sales.
 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Bulbospinal Muscular Atrophy Drugs Market

Request Now !

Bulbospinal muscular atrophy, also referred as Kennedy disease, is a disorder that affects the specific nerve cells in the brain that controls muscle movement. These nerve cells originate in the spinal cord and the part of the brain that is connected to the spinal cord. It is an X-linked autosomal recessive progressive neurological condition that causes the proximal and bulbar muscles to weaken. The illness is caused by the loss of nerve cells in the brain stem and spinal cord, which causes impulses from the brain to muscles to stop working. Bulbospinal muscular atrophy affects patients' ability to speak, stand, walk, and regulate their head movements. In severe condition, patients may have difficulty in swallowing and breathing. This condition primarily affects men and does not affect women, who are protected by their low testosterone levels in the body, which accounts for the condition's sex-limited inheritance pattern.

COVID-19 Impact Analysis

COVID-19 is an infectious disease that originated in Hubei province of the Wuhan city in China in late December. The highly contagious disease, caused by a virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is transmitted from human to human. Since the outbreak in December 2019, the disease has spread to almost 213 countries around the globe with the World Health Organization declaring it a public health emergency on March 11, 2020.

Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing shortage of these drugs. Thus, the pharmaceutical and biotechnology industries are expected witness a significant growth in the future, owing to the demand for vaccine and treatment drugs for COVID-19. This, in turn, is expected to have a significant impact on the bulbospinal muscular atrophy drugs market.

Top Impacting Factors

Rise in requirement for treatment,  rise in R&D activities to develop novel treatment for  bulbospinal muscular atrophy, initiatives undertaken by  various public as well as government & nongovernment organizations to create awareness regarding bulbospinal muscular atrophy are some factors which boost the market growth.

According to National Organization for Rare Disorders, bulbospinal muscular atrophy or Kennedy disease is a rare type of disorder and it affects 1 in 350,000 males and rarely seen in females. Hence, increase in the number of patients suffering from bulbospinal muscular atrophy boosts the market growth.

In addition, increase in healthcare expenditure, collaborations & partnerships between key players to facilitate drug development, rise in R&D to improve quality of drugs, launches of novel developed drug in market are some factors that contribute toward the bulbospinal muscular atrophy drugs market.   .

Market Trends

New Product Launches to Flourish the Market

In August 2018, Takeda Pharmaceutical Company Limited developed Leuprorelin, a gonadotropin-releasing hormone (GnRH) agonist, for the treatment of bulbospinal muscular atrophy. If approved, this drug will provide a potential treatment for patients with bulbospinal muscular atrophy.

Increase in Number of Clinical Trials for Drug

In April 2019, Novartis AG developed BVS857, a novel drug for the treatment of bulbospinal muscular atrophy, currently ongoing in phase ll clinical trial. If approved, this novel drug will provide a potential treatment for patients with bulbospinal muscular atrophy and help in improving their life. Hence, increase in number of clinical trials for drug will further boost the market growth.

Key Benefits of the Report

  • This study presents the analytical depiction of the bulbospinal muscular atrophy drugs industry along with the current trends and future estimations to determine the imminent investment pockets.
  • The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the market share.
  • The current market is quantitatively analyzed to highlight the market growth scenario.
  • Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
  • The report provides a detailed market analysis depending on competitive intensity and how the competition will take shape in coming years.

Questions Answered in the Bulbospinal Muscular Atrophy Drugs Market Report

  • Which are the leading players active in the bulbospinal muscular atrophy drugs market?
  • What are the current trends that will influence the market in the next few years?
  • What are the driving factors, restraints, and opportunities of the market?
  • What future projections would help in taking further strategic steps?
  • What is " bulbospinal muscular atrophy market"?
  • What is " bulbospinal muscular atrophy drugs market " prediction in the future?
  • Who are the leading global players in the " bulbospinal muscular atrophy drugs market"?
  • What are the current trends and predicted trends?
  • What are the key benefits of the "bulbospinal muscular atrophy drugs market” report? 

 Bulbospinal Muscular Atrophy Drugs Market Report Highlights

Aspects Details
By Product
  • Leuprorelin
  • Dutasterid
  • Others
By End User
  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (France, Germany, Italy, Spain, UK, Rest of Europe)
  • Asia-Pacific  (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific)
  • LAMEA  (Brazil, South Africa, Saudi Arabia, UAE, Rest of LAMEA)
Key Market Players Salarius Pharmaceuticals Inc., Novartis AG, Boehringer Ingelheim International GmbH, Leadiant Biosciences Inc., Ionis Pharmaceuticals Inc., Abbott, Pfizer Inc., F. Hoffmann-La Roche Ltd., Regeneron Pharmaceuticals Inc., Novo Nordisk A/S
 

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

    • 3.6. COVID-19 Impact Analysis

  • CHAPTER 4: BULBOSPINAL MUSCULAR ATROPHY DRUGS MARKET, BY PRODUCT

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Product

    • 4.2. Leuprorelin

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Dutasterid

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

    • 4.4. Others

      • 4.4.1. Key Market Trends, Growth Factors and Opportunities

      • 4.4.2. Market Size and Forecast, By Region

      • 4.4.3. Market Share Analysis, By Country

  • CHAPTER 5: BULBOSPINAL MUSCULAR ATROPHY DRUGS MARKET, BY END USER

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By End User

    • 5.2. Hospitals

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Homecare

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

    • 5.4. Specialty Clinics

      • 5.4.1. Key Market Trends, Growth Factors and Opportunities

      • 5.4.2. Market Size and Forecast, By Region

      • 5.4.3. Market Share Analysis, By Country

    • 5.5. Others

      • 5.5.1. Key Market Trends, Growth Factors and Opportunities

      • 5.5.2. Market Size and Forecast, By Region

      • 5.5.3. Market Share Analysis, By Country

  • CHAPTER 6: BULBOSPINAL MUSCULAR ATROPHY DRUGS MARKET, BY REGION

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By Region

    • 6.2. North America

      • 6.2.1. Key Market Trends and Opportunities

      • 6.2.2. Market Size and Forecast, By Product

      • 6.2.3. Market Size and Forecast, By End User

      • 6.2.4. Market Size and Forecast, By Country

      • 6.2.5. U.S. Bulbospinal Muscular Atrophy Drugs Market

        • 6.2.5.1. Market Size and Forecast, By Product
        • 6.2.5.2. Market Size and Forecast, By End User

      • 6.2.6. Canada Bulbospinal Muscular Atrophy Drugs Market

        • 6.2.6.1. Market Size and Forecast, By Product
        • 6.2.6.2. Market Size and Forecast, By End User

      • 6.2.7. Mexico Bulbospinal Muscular Atrophy Drugs Market

        • 6.2.7.1. Market Size and Forecast, By Product
        • 6.2.7.2. Market Size and Forecast, By End User

    • 6.3. Europe

      • 6.3.1. Key Market Trends and Opportunities

      • 6.3.2. Market Size and Forecast, By Product

      • 6.3.3. Market Size and Forecast, By End User

      • 6.3.4. Market Size and Forecast, By Country

      • 6.3.5. France Bulbospinal Muscular Atrophy Drugs Market

        • 6.3.5.1. Market Size and Forecast, By Product
        • 6.3.5.2. Market Size and Forecast, By End User

      • 6.3.6. Germany Bulbospinal Muscular Atrophy Drugs Market

        • 6.3.6.1. Market Size and Forecast, By Product
        • 6.3.6.2. Market Size and Forecast, By End User

      • 6.3.7. Italy Bulbospinal Muscular Atrophy Drugs Market

        • 6.3.7.1. Market Size and Forecast, By Product
        • 6.3.7.2. Market Size and Forecast, By End User

      • 6.3.8. Spain Bulbospinal Muscular Atrophy Drugs Market

        • 6.3.8.1. Market Size and Forecast, By Product
        • 6.3.8.2. Market Size and Forecast, By End User

      • 6.3.9. UK Bulbospinal Muscular Atrophy Drugs Market

        • 6.3.9.1. Market Size and Forecast, By Product
        • 6.3.9.2. Market Size and Forecast, By End User

      • 6.3.10. Russia Bulbospinal Muscular Atrophy Drugs Market

        • 6.3.10.1. Market Size and Forecast, By Product
        • 6.3.10.2. Market Size and Forecast, By End User

      • 6.3.11. Rest Of Europe Bulbospinal Muscular Atrophy Drugs Market

        • 6.3.11.1. Market Size and Forecast, By Product
        • 6.3.11.2. Market Size and Forecast, By End User

    • 6.4. Asia-Pacific

      • 6.4.1. Key Market Trends and Opportunities

      • 6.4.2. Market Size and Forecast, By Product

      • 6.4.3. Market Size and Forecast, By End User

      • 6.4.4. Market Size and Forecast, By Country

      • 6.4.5. China Bulbospinal Muscular Atrophy Drugs Market

        • 6.4.5.1. Market Size and Forecast, By Product
        • 6.4.5.2. Market Size and Forecast, By End User

      • 6.4.6. Japan Bulbospinal Muscular Atrophy Drugs Market

        • 6.4.6.1. Market Size and Forecast, By Product
        • 6.4.6.2. Market Size and Forecast, By End User

      • 6.4.7. India Bulbospinal Muscular Atrophy Drugs Market

        • 6.4.7.1. Market Size and Forecast, By Product
        • 6.4.7.2. Market Size and Forecast, By End User

      • 6.4.8. South Korea Bulbospinal Muscular Atrophy Drugs Market

        • 6.4.8.1. Market Size and Forecast, By Product
        • 6.4.8.2. Market Size and Forecast, By End User

      • 6.4.9. Australia Bulbospinal Muscular Atrophy Drugs Market

        • 6.4.9.1. Market Size and Forecast, By Product
        • 6.4.9.2. Market Size and Forecast, By End User

      • 6.4.10. Thailand Bulbospinal Muscular Atrophy Drugs Market

        • 6.4.10.1. Market Size and Forecast, By Product
        • 6.4.10.2. Market Size and Forecast, By End User

      • 6.4.11. Malaysia Bulbospinal Muscular Atrophy Drugs Market

        • 6.4.11.1. Market Size and Forecast, By Product
        • 6.4.11.2. Market Size and Forecast, By End User

      • 6.4.12. Indonesia Bulbospinal Muscular Atrophy Drugs Market

        • 6.4.12.1. Market Size and Forecast, By Product
        • 6.4.12.2. Market Size and Forecast, By End User

      • 6.4.13. Rest of Asia Pacific Bulbospinal Muscular Atrophy Drugs Market

        • 6.4.13.1. Market Size and Forecast, By Product
        • 6.4.13.2. Market Size and Forecast, By End User

    • 6.5. LAMEA

      • 6.5.1. Key Market Trends and Opportunities

      • 6.5.2. Market Size and Forecast, By Product

      • 6.5.3. Market Size and Forecast, By End User

      • 6.5.4. Market Size and Forecast, By Country

      • 6.5.5. Brazil Bulbospinal Muscular Atrophy Drugs Market

        • 6.5.5.1. Market Size and Forecast, By Product
        • 6.5.5.2. Market Size and Forecast, By End User

      • 6.5.6. South Africa Bulbospinal Muscular Atrophy Drugs Market

        • 6.5.6.1. Market Size and Forecast, By Product
        • 6.5.6.2. Market Size and Forecast, By End User

      • 6.5.7. Saudi Arabia Bulbospinal Muscular Atrophy Drugs Market

        • 6.5.7.1. Market Size and Forecast, By Product
        • 6.5.7.2. Market Size and Forecast, By End User

      • 6.5.8. UAE Bulbospinal Muscular Atrophy Drugs Market

        • 6.5.8.1. Market Size and Forecast, By Product
        • 6.5.8.2. Market Size and Forecast, By End User

      • 6.5.9. Argentina Bulbospinal Muscular Atrophy Drugs Market

        • 6.5.9.1. Market Size and Forecast, By Product
        • 6.5.9.2. Market Size and Forecast, By End User

      • 6.5.10. Rest of LAMEA Bulbospinal Muscular Atrophy Drugs Market

        • 6.5.10.1. Market Size and Forecast, By Product
        • 6.5.10.2. Market Size and Forecast, By End User

  • CHAPTER 7: COMPETITIVE LANDSCAPE

    • 7.1. Introduction

    • 7.2. Top Winning Strategies

    • 7.3. Product Mapping Of Top 10 Player

    • 7.4. Competitive Dashboard

    • 7.5. Competitive Heatmap

    • 7.6. Top Player Positioning,2022

  • CHAPTER 8: COMPANY PROFILES

    • 8.1. Novartis AG

      • 8.1.1. Company Overview

      • 8.1.2. Key Executives

      • 8.1.3. Company Snapshot

      • 8.1.4. Operating Business Segments

      • 8.1.5. Product Portfolio

      • 8.1.6. Business Performance

      • 8.1.7. Key Strategic Moves and Developments

    • 8.2. F. Hoffmann-La Roche Ltd.

      • 8.2.1. Company Overview

      • 8.2.2. Key Executives

      • 8.2.3. Company Snapshot

      • 8.2.4. Operating Business Segments

      • 8.2.5. Product Portfolio

      • 8.2.6. Business Performance

      • 8.2.7. Key Strategic Moves and Developments

    • 8.3. Boehringer Ingelheim International GmbH

      • 8.3.1. Company Overview

      • 8.3.2. Key Executives

      • 8.3.3. Company Snapshot

      • 8.3.4. Operating Business Segments

      • 8.3.5. Product Portfolio

      • 8.3.6. Business Performance

      • 8.3.7. Key Strategic Moves and Developments

    • 8.4. Pfizer Inc.

      • 8.4.1. Company Overview

      • 8.4.2. Key Executives

      • 8.4.3. Company Snapshot

      • 8.4.4. Operating Business Segments

      • 8.4.5. Product Portfolio

      • 8.4.6. Business Performance

      • 8.4.7. Key Strategic Moves and Developments

    • 8.5. Ionis Pharmaceuticals Inc.

      • 8.5.1. Company Overview

      • 8.5.2. Key Executives

      • 8.5.3. Company Snapshot

      • 8.5.4. Operating Business Segments

      • 8.5.5. Product Portfolio

      • 8.5.6. Business Performance

      • 8.5.7. Key Strategic Moves and Developments

    • 8.6. Regeneron Pharmaceuticals Inc.

      • 8.6.1. Company Overview

      • 8.6.2. Key Executives

      • 8.6.3. Company Snapshot

      • 8.6.4. Operating Business Segments

      • 8.6.5. Product Portfolio

      • 8.6.6. Business Performance

      • 8.6.7. Key Strategic Moves and Developments

    • 8.7. Salarius Pharmaceuticals Inc.

      • 8.7.1. Company Overview

      • 8.7.2. Key Executives

      • 8.7.3. Company Snapshot

      • 8.7.4. Operating Business Segments

      • 8.7.5. Product Portfolio

      • 8.7.6. Business Performance

      • 8.7.7. Key Strategic Moves and Developments

    • 8.8. Leadiant Biosciences Inc.

      • 8.8.1. Company Overview

      • 8.8.2. Key Executives

      • 8.8.3. Company Snapshot

      • 8.8.4. Operating Business Segments

      • 8.8.5. Product Portfolio

      • 8.8.6. Business Performance

      • 8.8.7. Key Strategic Moves and Developments

    • 8.9. Abbott

      • 8.9.1. Company Overview

      • 8.9.2. Key Executives

      • 8.9.3. Company Snapshot

      • 8.9.4. Operating Business Segments

      • 8.9.5. Product Portfolio

      • 8.9.6. Business Performance

      • 8.9.7. Key Strategic Moves and Developments

    • 8.10. Novo Nordisk A/S

      • 8.10.1. Company Overview

      • 8.10.2. Key Executives

      • 8.10.3. Company Snapshot

      • 8.10.4. Operating Business Segments

      • 8.10.5. Product Portfolio

      • 8.10.6. Business Performance

      • 8.10.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL BULBOSPINAL MUSCULAR ATROPHY DRUGS MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 2. GLOBAL BULBOSPINAL MUSCULAR ATROPHY DRUGS MARKET FOR LEUPRORELIN, BY REGION, 2022-2032 ($MILLION)
  • TABLE 3. GLOBAL BULBOSPINAL MUSCULAR ATROPHY DRUGS MARKET FOR DUTASTERID, BY REGION, 2022-2032 ($MILLION)
  • TABLE 4. GLOBAL BULBOSPINAL MUSCULAR ATROPHY DRUGS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 5. GLOBAL BULBOSPINAL MUSCULAR ATROPHY DRUGS MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 6. GLOBAL BULBOSPINAL MUSCULAR ATROPHY DRUGS MARKET FOR HOSPITALS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 7. GLOBAL BULBOSPINAL MUSCULAR ATROPHY DRUGS MARKET FOR HOMECARE, BY REGION, 2022-2032 ($MILLION)
  • TABLE 8. GLOBAL BULBOSPINAL MUSCULAR ATROPHY DRUGS MARKET FOR SPECIALTY CLINICS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 9. GLOBAL BULBOSPINAL MUSCULAR ATROPHY DRUGS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 10. GLOBAL BULBOSPINAL MUSCULAR ATROPHY DRUGS MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 11. NORTH AMERICA BULBOSPINAL MUSCULAR ATROPHY DRUGS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 12. NORTH AMERICA BULBOSPINAL MUSCULAR ATROPHY DRUGS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 13. NORTH AMERICA BULBOSPINAL MUSCULAR ATROPHY DRUGS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 14. U.S. BULBOSPINAL MUSCULAR ATROPHY DRUGS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 15. U.S. BULBOSPINAL MUSCULAR ATROPHY DRUGS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 16. CANADA BULBOSPINAL MUSCULAR ATROPHY DRUGS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 17. CANADA BULBOSPINAL MUSCULAR ATROPHY DRUGS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 18. MEXICO BULBOSPINAL MUSCULAR ATROPHY DRUGS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 19. MEXICO BULBOSPINAL MUSCULAR ATROPHY DRUGS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 20. EUROPE BULBOSPINAL MUSCULAR ATROPHY DRUGS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 21. EUROPE BULBOSPINAL MUSCULAR ATROPHY DRUGS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 22. EUROPE BULBOSPINAL MUSCULAR ATROPHY DRUGS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 23. FRANCE BULBOSPINAL MUSCULAR ATROPHY DRUGS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 24. FRANCE BULBOSPINAL MUSCULAR ATROPHY DRUGS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 25. GERMANY BULBOSPINAL MUSCULAR ATROPHY DRUGS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 26. GERMANY BULBOSPINAL MUSCULAR ATROPHY DRUGS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 27. ITALY BULBOSPINAL MUSCULAR ATROPHY DRUGS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 28. ITALY BULBOSPINAL MUSCULAR ATROPHY DRUGS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 29. SPAIN BULBOSPINAL MUSCULAR ATROPHY DRUGS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 30. SPAIN BULBOSPINAL MUSCULAR ATROPHY DRUGS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 31. UK BULBOSPINAL MUSCULAR ATROPHY DRUGS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 32. UK BULBOSPINAL MUSCULAR ATROPHY DRUGS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 33. RUSSIA BULBOSPINAL MUSCULAR ATROPHY DRUGS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 34. RUSSIA BULBOSPINAL MUSCULAR ATROPHY DRUGS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 35. REST OF EUROPE BULBOSPINAL MUSCULAR ATROPHY DRUGS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 36. REST OF EUROPE BULBOSPINAL MUSCULAR ATROPHY DRUGS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 37. ASIA-PACIFIC BULBOSPINAL MUSCULAR ATROPHY DRUGS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 38. ASIA-PACIFIC BULBOSPINAL MUSCULAR ATROPHY DRUGS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 39. ASIA-PACIFIC BULBOSPINAL MUSCULAR ATROPHY DRUGS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 40. CHINA BULBOSPINAL MUSCULAR ATROPHY DRUGS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 41. CHINA BULBOSPINAL MUSCULAR ATROPHY DRUGS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 42. JAPAN BULBOSPINAL MUSCULAR ATROPHY DRUGS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 43. JAPAN BULBOSPINAL MUSCULAR ATROPHY DRUGS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 44. INDIA BULBOSPINAL MUSCULAR ATROPHY DRUGS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 45. INDIA BULBOSPINAL MUSCULAR ATROPHY DRUGS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 46. SOUTH KOREA BULBOSPINAL MUSCULAR ATROPHY DRUGS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 47. SOUTH KOREA BULBOSPINAL MUSCULAR ATROPHY DRUGS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 48. AUSTRALIA BULBOSPINAL MUSCULAR ATROPHY DRUGS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 49. AUSTRALIA BULBOSPINAL MUSCULAR ATROPHY DRUGS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 50. THAILAND BULBOSPINAL MUSCULAR ATROPHY DRUGS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 51. THAILAND BULBOSPINAL MUSCULAR ATROPHY DRUGS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 52. MALAYSIA BULBOSPINAL MUSCULAR ATROPHY DRUGS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 53. MALAYSIA BULBOSPINAL MUSCULAR ATROPHY DRUGS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 54. INDONESIA BULBOSPINAL MUSCULAR ATROPHY DRUGS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 55. INDONESIA BULBOSPINAL MUSCULAR ATROPHY DRUGS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 56. REST OF ASIA PACIFIC BULBOSPINAL MUSCULAR ATROPHY DRUGS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 57. REST OF ASIA PACIFIC BULBOSPINAL MUSCULAR ATROPHY DRUGS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 58. LAMEA BULBOSPINAL MUSCULAR ATROPHY DRUGS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 59. LAMEA BULBOSPINAL MUSCULAR ATROPHY DRUGS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 60. LAMEA BULBOSPINAL MUSCULAR ATROPHY DRUGS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 61. BRAZIL BULBOSPINAL MUSCULAR ATROPHY DRUGS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 62. BRAZIL BULBOSPINAL MUSCULAR ATROPHY DRUGS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 63. SOUTH AFRICA BULBOSPINAL MUSCULAR ATROPHY DRUGS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 64. SOUTH AFRICA BULBOSPINAL MUSCULAR ATROPHY DRUGS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 65. SAUDI ARABIA BULBOSPINAL MUSCULAR ATROPHY DRUGS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 66. SAUDI ARABIA BULBOSPINAL MUSCULAR ATROPHY DRUGS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 67. UAE BULBOSPINAL MUSCULAR ATROPHY DRUGS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 68. UAE BULBOSPINAL MUSCULAR ATROPHY DRUGS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 69. ARGENTINA BULBOSPINAL MUSCULAR ATROPHY DRUGS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 70. ARGENTINA BULBOSPINAL MUSCULAR ATROPHY DRUGS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 71. REST OF LAMEA BULBOSPINAL MUSCULAR ATROPHY DRUGS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 72. REST OF LAMEA BULBOSPINAL MUSCULAR ATROPHY DRUGS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 73. NOVARTIS AG: KEY EXECUTIVES
  • TABLE 74. NOVARTIS AG: COMPANY SNAPSHOT
  • TABLE 75. NOVARTIS AG: OPERATING SEGMENTS
  • TABLE 76. NOVARTIS AG: PRODUCT PORTFOLIO
  • TABLE 77. NOVARTIS AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 78. F. HOFFMANN-LA ROCHE LTD.: KEY EXECUTIVES
  • TABLE 79. F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT
  • TABLE 80. F. HOFFMANN-LA ROCHE LTD.: OPERATING SEGMENTS
  • TABLE 81. F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO
  • TABLE 82. F. HOFFMANN-LA ROCHE LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 83. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: KEY EXECUTIVES
  • TABLE 84. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY SNAPSHOT
  • TABLE 85. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: OPERATING SEGMENTS
  • TABLE 86. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: PRODUCT PORTFOLIO
  • TABLE 87. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 88. PFIZER INC.: KEY EXECUTIVES
  • TABLE 89. PFIZER INC.: COMPANY SNAPSHOT
  • TABLE 90. PFIZER INC.: OPERATING SEGMENTS
  • TABLE 91. PFIZER INC.: PRODUCT PORTFOLIO
  • TABLE 92. PFIZER INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 93. IONIS PHARMACEUTICALS INC.: KEY EXECUTIVES
  • TABLE 94. IONIS PHARMACEUTICALS INC.: COMPANY SNAPSHOT
  • TABLE 95. IONIS PHARMACEUTICALS INC.: OPERATING SEGMENTS
  • TABLE 96. IONIS PHARMACEUTICALS INC.: PRODUCT PORTFOLIO
  • TABLE 97. IONIS PHARMACEUTICALS INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 98. REGENERON PHARMACEUTICALS INC.: KEY EXECUTIVES
  • TABLE 99. REGENERON PHARMACEUTICALS INC.: COMPANY SNAPSHOT
  • TABLE 100. REGENERON PHARMACEUTICALS INC.: OPERATING SEGMENTS
  • TABLE 101. REGENERON PHARMACEUTICALS INC.: PRODUCT PORTFOLIO
  • TABLE 102. REGENERON PHARMACEUTICALS INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 103. SALARIUS PHARMACEUTICALS INC.: KEY EXECUTIVES
  • TABLE 104. SALARIUS PHARMACEUTICALS INC.: COMPANY SNAPSHOT
  • TABLE 105. SALARIUS PHARMACEUTICALS INC.: OPERATING SEGMENTS
  • TABLE 106. SALARIUS PHARMACEUTICALS INC.: PRODUCT PORTFOLIO
  • TABLE 107. SALARIUS PHARMACEUTICALS INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 108. LEADIANT BIOSCIENCES INC.: KEY EXECUTIVES
  • TABLE 109. LEADIANT BIOSCIENCES INC.: COMPANY SNAPSHOT
  • TABLE 110. LEADIANT BIOSCIENCES INC.: OPERATING SEGMENTS
  • TABLE 111. LEADIANT BIOSCIENCES INC.: PRODUCT PORTFOLIO
  • TABLE 112. LEADIANT BIOSCIENCES INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 113. ABBOTT: KEY EXECUTIVES
  • TABLE 114. ABBOTT: COMPANY SNAPSHOT
  • TABLE 115. ABBOTT: OPERATING SEGMENTS
  • TABLE 116. ABBOTT: PRODUCT PORTFOLIO
  • TABLE 117. ABBOTT: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 118. NOVO NORDISK A/S: KEY EXECUTIVES
  • TABLE 119. NOVO NORDISK A/S: COMPANY SNAPSHOT
  • TABLE 120. NOVO NORDISK A/S: OPERATING SEGMENTS
  • TABLE 121. NOVO NORDISK A/S: PRODUCT PORTFOLIO
  • TABLE 122. NOVO NORDISK A/S: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL BULBOSPINAL MUSCULAR ATROPHY DRUGS MARKET SEGMENTATION
  • FIGURE 2. GLOBAL BULBOSPINAL MUSCULAR ATROPHY DRUGS MARKET
  • FIGURE 3. SEGMENTATION BULBOSPINAL MUSCULAR ATROPHY DRUGS MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN BULBOSPINAL MUSCULAR ATROPHY DRUGS MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALBULBOSPINAL MUSCULAR ATROPHY DRUGS MARKET
  • FIGURE 11. BULBOSPINAL MUSCULAR ATROPHY DRUGS MARKET SEGMENTATION, BY BY PRODUCT
  • FIGURE 12. BULBOSPINAL MUSCULAR ATROPHY DRUGS MARKET FOR LEUPRORELIN, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 13. BULBOSPINAL MUSCULAR ATROPHY DRUGS MARKET FOR DUTASTERID, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 14. BULBOSPINAL MUSCULAR ATROPHY DRUGS MARKET FOR OTHERS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 15. BULBOSPINAL MUSCULAR ATROPHY DRUGS MARKET SEGMENTATION, BY BY END USER
  • FIGURE 16. BULBOSPINAL MUSCULAR ATROPHY DRUGS MARKET FOR HOSPITALS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 17. BULBOSPINAL MUSCULAR ATROPHY DRUGS MARKET FOR HOMECARE, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 18. BULBOSPINAL MUSCULAR ATROPHY DRUGS MARKET FOR SPECIALTY CLINICS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 19. BULBOSPINAL MUSCULAR ATROPHY DRUGS MARKET FOR OTHERS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 20. TOP WINNING STRATEGIES, BY YEAR, 2020-2022*
  • FIGURE 21. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2020-2022*
  • FIGURE 22. TOP WINNING STRATEGIES, BY COMPANY, 2020-2022*
  • FIGURE 23. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 24. COMPETITIVE DASHBOARD
  • FIGURE 25. COMPETITIVE HEATMAP: BULBOSPINAL MUSCULAR ATROPHY DRUGS MARKET
  • FIGURE 26. Top player positioning, 2022
  • FIGURE 27. NOVARTIS AG: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 28. NOVARTIS AG: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 29. NOVARTIS AG: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 30. F. HOFFMANN-LA ROCHE LTD.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 31. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 32. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 33. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 34. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 35. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 36. PFIZER INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 37. PFIZER INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 38. PFIZER INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 39. IONIS PHARMACEUTICALS INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 40. IONIS PHARMACEUTICALS INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 41. IONIS PHARMACEUTICALS INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 42. REGENERON PHARMACEUTICALS INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 43. REGENERON PHARMACEUTICALS INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 44. REGENERON PHARMACEUTICALS INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 45. SALARIUS PHARMACEUTICALS INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 46. SALARIUS PHARMACEUTICALS INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 47. SALARIUS PHARMACEUTICALS INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 48. LEADIANT BIOSCIENCES INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 49. LEADIANT BIOSCIENCES INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 50. LEADIANT BIOSCIENCES INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 51. ABBOTT: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 52. ABBOTT: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 53. ABBOTT: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 54. NOVO NORDISK A/S: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 55. NOVO NORDISK A/S: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 56. NOVO NORDISK A/S: REVENUE SHARE, BY REGION, 2032 (%)

 
 
With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

  • Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
  • Technologically sophisticated and reliable insights through well audited and veracious research methodology
  • Sovereign research proceeds that present a tangible depiction of marketplace


With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, web-casts and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast


Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develops analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth and forecasts


Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

  • Chief executives and VPs of leading corporations specific to industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)


Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.

PURCHASE OPTIONS

Call or Email us

U.S.-Canada Toll-free: +1-800-792-5285
Int'l : +1-503-894-6022
Europe : +44-845-528-1300
Email : help@alliedmarketresearch.com

Looking for Customization?

 Customization Request

Have a Question?

 Speak with Analyst

Any Confusion?

 Inquire Before Buying

Have a glance of the Report

  Enquiry Now
RELATED TAGS

Purchase Full Report of
Bulbospinal Muscular Atrophy Drugs Market

Start reading.
This Report and over 67,404+ more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,690
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  • Free industry update
    (Within 180 days)
  • Free report update in next update cycle
  • Data Pack
  • $3,930
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Single User
  • $5,820
  • Restricted to one authorized user
  • One print only
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Five Users
  • $6,540
  • Limited to five authorized users
  • Print upto five copies
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Enterprise
    License/PDF

  • $9,870
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Library
    Membership

  • $999 $ 1,175
    Per User/ Per month/ Billed annually
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

RELATED REPORTS
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers